University of Edinburgh
Investigating integrin-linked kinase as a novel therapeutic vulnerability in glioblastoma
Abstract
dc:description.abstractGlioblastoma (GBM) is the most common and aggressive primary brain tumour in adults. Despite multimodal treatment entailing surgical resection, chemotherapy, and radiotherapy, patient survival remains dismal, highlighting and the urgent need for more effective therapeutic strategies. Integrin-linked kinase (ILK) is a cell-matrix adhesion protein overexpressed in several cancers and has previously been identified as a therapeutic target contributing to malignant features of GBM. As cancer cells rarely respond robustly to loss of function of a single protein target and GBM stem cells (GSCs) are key drivers of treatment resistance and relapse, this project aims to (i) establish and characterise novel GSC models for the study of ILK; (ii) use these models to investigate the role of ILK in resistance to radiotherapy, the standard-of-care treatment in GBM; (iii) identify candidate compounds that synergise with abrogation of ILK. The development of effective therapeutic opportunities for GBM has been limited by the lack of stem cell-derived models. The first results chapter details the generation of ILK knock-out GSCs, providing a suitable patient-derived GSC model for the in vitro and in vivo investigation of ILK loss. ILK deletion resulted in adhesion defects and protein changes were analysed by reverse-phase protein array (RPPA). The second results chapter examines the impact of ILK deletion on the cellular response to ionising radiation, using clonogenic survival and viability assays, cell cycle profiling, and RPPA analysis to reveal ILK's role in radio-resistance, and the activation of the DNA damage response and survival pathways. In the third results chapter, high-throughput chemical-genetic screens were performed using four target-annotated small-molecule compound libraries, Library of Pharmacologically Active Compounds (LOPAC; 1280 compounds), Comprehensive anti-Cancer Chemical library (C3L; 789 compounds), TargetMol Anticancer library (331 compounds), and TargetMol FDA-Approved Drug library (1418 compounds) at four concentrations (30 nM, 100 nM, 300 nM, 1 μM) using cell viability as the primary assay endpoint. Compounds which demonstrated increased sensitivity with ILK-deficiency were validated via dose-response curves. Afatinib, an epidermal growth factor receptor inhibitor, was the most promising compound, exhibiting the greatest effect in ILK-deficient cells. As such, it was examined in combination with IR (CIX1 X-Ray cabinet) in three GSC models, and downstream protein alterations were profiled via RPPA. Overall, this work developed novel GSC models suitable for the investigation of ILK in GBM, demonstrated a role for ILK in mediating radio-resistance in GBM, and identified afatinib as a potential therapeutic strategy in combination with abrogation of ILK or future ILK-targeting compounds.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Romano, Marianna Sophia
- Advisors dc:contributor.advisor
-
- Carragher, Neil
- Loftus, Alex
- Birch, Joanna
Subjects
dc:subject × 5Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.7488/era/7823